Andra AP fonden Grows Stock Holdings in AbbVie Inc. $ABBV

Andra AP fonden increased its position in AbbVie Inc. (NYSE:ABBV) by 43.4% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 107,300 shares of the company’s stock after purchasing an additional 32,500 shares during the period. Andra AP fonden’s holdings in AbbVie were worth $24,844,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Evolution Wealth Management Inc. bought a new position in AbbVie during the second quarter valued at approximately $26,000. Spurstone Advisory Services LLC purchased a new stake in shares of AbbVie in the second quarter worth $28,000. Financial Gravity Companies Inc. bought a new stake in shares of AbbVie during the 2nd quarter valued at $36,000. Delos Wealth Advisors LLC bought a new stake in shares of AbbVie during the 2nd quarter valued at $39,000. Finally, Redmont Wealth Advisors LLC bought a new stake in AbbVie during the 3rd quarter valued at approximately $41,000. 70.23% of the stock is currently owned by institutional investors.

AbbVie Trading Down 1.0%

Shares of NYSE:ABBV opened at $224.66 on Friday. The business has a 50-day moving average price of $224.26 and a 200 day moving average price of $222.71. AbbVie Inc. has a 12-month low of $164.39 and a 12-month high of $244.81. The company has a market capitalization of $397.24 billion, a price-to-earnings ratio of 95.19, a PEG ratio of 0.79 and a beta of 0.35.

AbbVie (NYSE:ABBV) last posted its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, beating the consensus estimate of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The firm had revenue of $16.62 billion during the quarter, compared to the consensus estimate of $16.39 billion. During the same quarter last year, the firm earned $2.16 EPS. The firm’s revenue for the quarter was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, equities research analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be given a $1.73 dividend. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a yield of 3.1%. AbbVie’s dividend payout ratio (DPR) is currently 293.22%.

Analysts Set New Price Targets

ABBV has been the topic of several recent research reports. Morgan Stanley upped their price objective on AbbVie from $269.00 to $270.00 and gave the stock an “overweight” rating in a report on Thursday, February 5th. BMO Capital Markets reissued an “outperform” rating and issued a $258.00 price objective on shares of AbbVie in a research report on Thursday, January 15th. Raymond James Financial set a $256.00 price objective on shares of AbbVie in a research note on Monday, November 3rd. Wall Street Zen lowered shares of AbbVie from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 3rd. Finally, The Goldman Sachs Group restated a “neutral” rating and set a $223.00 price objective on shares of AbbVie in a report on Wednesday, January 28th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $253.15.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.